A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants with Advanced Solid Tumors

Phase 2, open-label trial of BMS-986482 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), melanoma and 6 more (5 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs), AEs leading to discontinuation, and death. Planned start Nov 2025; status: authorised.